Prazosin Hydrochloride: Class II Recall Update

08 Apr 20264 min read0 views

GIST

Product: PRAZOSIN HYDROCHLORIDE Classification: Class II Reason for recall: cGMP deviation: detection of Nitrosamine Drug Substance-Related Impurities, N-nitroso-prazosin impurity C (NNP) above acceptable limits. Product description: Prazosin Hydrochloride Capsules, USP, 1mg, 100-count bottle, Rx Only, Manufactured for: Biocon Pharma Inc., Iselin, NJ, Manufactured by: Appco Pharma LLC, Piscataway, NJ, NDC 70377-066-11. Recalling firm: Appco Pharma LLC Product type: Drugs

Clinical Editorial

Summary

FDA MedWatch published a clinical safety alert in Pharmacology on 08 Apr 2026.

The item focuses on PRAZOSIN HYDROCHLORIDE: Class II recall update.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

BMJRelated by Specialty

ASPIRIN LOW DOSE (aspirin) tablet, delayed release [United Natural Foods, Inc. dba UNFI]

Pharmacology • 23 Apr 2026

Feed Metadata

Source

FDA MedWatch

Prazosin Hydrochloride: Class II Recall Update

GIST

Clinical Editorial

Summary

Source Reference

Related by Condition/Drug

FDA Blocks Publication Of Studies On Covid-19 And Shingles Vaccines

FLUOCINONIDE: Class II recall update

MGC HEALTH: Class II recall update

ZITSTICKA KILLA ACNE EXTRA STRENGTH (salicylic acid) patch [Brndxl LLC]

ASPIRIN LOW DOSE (aspirin) tablet, delayed release [United Natural Foods, Inc. dba UNFI]